MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.370
EU - Europa 2.651
AS - Asia 1.730
SA - Sud America 249
AF - Africa 58
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.294
GB - Regno Unito 1.289
CN - Cina 618
SG - Singapore 498
IT - Italia 336
HK - Hong Kong 265
DE - Germania 234
SE - Svezia 222
BR - Brasile 189
RU - Federazione Russa 109
FR - Francia 105
UA - Ucraina 102
FI - Finlandia 87
VN - Vietnam 73
TR - Turchia 66
IN - India 47
BG - Bulgaria 43
CA - Canada 43
ID - Indonesia 38
MA - Marocco 38
KR - Corea 34
AR - Argentina 26
BE - Belgio 17
ES - Italia 14
MX - Messico 14
PL - Polonia 14
IE - Irlanda 13
AU - Australia 12
CH - Svizzera 12
BD - Bangladesh 11
NL - Olanda 11
CZ - Repubblica Ceca 10
EC - Ecuador 10
IR - Iran 9
ZA - Sudafrica 9
LT - Lituania 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
CL - Cile 7
CO - Colombia 7
IQ - Iraq 7
JP - Giappone 7
PK - Pakistan 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
BZ - Belize 5
HU - Ungheria 5
PH - Filippine 5
KZ - Kazakistan 4
VE - Venezuela 4
DO - Repubblica Dominicana 3
EU - Europa 3
GP - Guadalupe 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
NO - Norvegia 3
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
IL - Israele 2
JO - Giordania 2
LB - Libano 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
CY - Cipro 1
EG - Egitto 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
LU - Lussemburgo 1
MM - Myanmar 1
MU - Mauritius 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SV - El Salvador 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 10.076
Salva come PNG Salva come JPEG
Città #
Southend 1.070
Fairfield 592
Ashburn 523
Santa Clara 492
Woodbridge 458
Singapore 318
Houston 274
Chandler 269
Hong Kong 265
Seattle 245
Wilmington 220
Ann Arbor 206
Cambridge 205
Jacksonville 202
Beijing 170
Dearborn 163
Nyköping 162
Hefei 137
London 112
New York 101
Modena 94
Chicago 71
Los Angeles 70
San Diego 57
Frankfurt am Main 56
Princeton 42
Sofia 42
Shanghai 41
Munich 39
Eugene 38
Helsinki 38
Council Bluffs 35
Moscow 35
Salt Lake City 33
Casablanca 32
Seoul 31
Milan 30
Izmir 29
Bremen 26
The Dalles 26
Bologna 24
Buffalo 23
Jakarta 23
Ho Chi Minh City 22
Columbus 20
Elk Grove Village 18
Brussels 17
Redwood City 17
Falls Church 16
Phoenix 16
São Paulo 16
Turku 15
Montreal 14
San Jose 14
Boardman 13
Dallas 13
Des Moines 13
Dublin 13
Hanoi 13
Nanjing 13
Rome 13
Denver 12
Fremont 12
Warsaw 12
New Delhi 11
Tampa 11
Dong Ket 10
Guangzhou 10
Brooklyn 9
Kunming 9
Norwalk 9
Rho 9
Indiana 8
Ottawa 8
San Giuliano Milanese 8
San Mateo 8
Stockholm 8
Boston 7
Buenos Aires 7
Carpi 7
Gurugram 7
Nuremberg 7
Poplar 7
Sterling 7
Tokyo 7
Toronto 7
Turin 7
Uppsala 7
Atlanta 6
Dongguan 6
Hebei 6
Manchester 6
Paris 6
Verona 6
Zhengzhou 6
Augusta 5
Baku 5
Belize City 5
Dhaka 5
Lancaster 5
Totale 7.693
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 581
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 447
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 380
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 353
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 340
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 323
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 295
A concise review of lenalidomide therapy for follicular lymphoma 288
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 286
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 278
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 270
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 265
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 261
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 261
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 255
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 254
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 250
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 243
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 241
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 240
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 238
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 238
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 233
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 231
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 230
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 229
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 224
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 214
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 207
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 207
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 203
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 199
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 197
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 195
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 191
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 176
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 168
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 163
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 149
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 147
Totale 10.150
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021732 0 0 0 0 0 94 81 122 67 114 176 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20261.613 241 144 204 385 586 53 0 0 0 0 0 0
Totale 10.150